| scholarly article | Q13442814 |
| P50 | author | Federico Cappuzzo | Q37392605 |
| Massimo Roncalli | Q37839163 | ||
| Lorenza Rimassa | Q38524354 | ||
| Giovanni Tallini | Q43484246 | ||
| Armando Santoro | Q56335956 | ||
| Luca Di Tommaso | Q57022086 | ||
| P2093 | author name string | P A Jänne | |
| E Rossi | |||
| G Finocchiaro | |||
| M Varella-Garcia | |||
| A Santoro | |||
| L Toschi | |||
| A J Holmes | |||
| M Skokan | |||
| C Carnaghi | |||
| C Ligorio | |||
| A Destro | |||
| S Gajapathy | |||
| P2860 | cites work | The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website | Q24645514 |
| Nonparametric Estimation from Incomplete Observations | Q25938997 | ||
| KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. | Q27824867 | ||
| MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling | Q27851406 | ||
| Cetuximab for the treatment of colorectal cancer. | Q27851419 | ||
| KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. | Q27851422 | ||
| Mutations of the BRAF gene in human cancer | Q27860760 | ||
| New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 | ||
| Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial | Q28036747 | ||
| Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer | Q28271324 | ||
| The tyrosine-phosphorylated hepatocyte growth factor/scatter factor receptor associates with phosphatidylinositol 3-kinase | Q28280668 | ||
| Molecular and cellular aspects of the insulin-like growth factor I receptor | Q28288023 | ||
| Insulin-like growth factors and their binding proteins: biological actions | Q28301853 | ||
| Cancer statistics, 2007 | Q29547293 | ||
| Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab | Q80704675 | ||
| Expression of the insulin-like growth factor-I receptor and proapoptotic Bax and Bak proteins in human colorectal cancer | Q81296298 | ||
| Phosphatidylinositol-3-OH kinase as a direct target of Ras | Q29620177 | ||
| Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer | Q33607176 | ||
| Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer | Q33913953 | ||
| The effects of insulin-like growth factors on tumorigenesis and neoplastic growth | Q33945357 | ||
| A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening | Q34492755 | ||
| Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. | Q34554584 | ||
| Serum hepatocyte growth factor as an index of disease status of patients with colorectal carcinoma | Q36115422 | ||
| Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy | Q36610301 | ||
| PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab | Q38584695 | ||
| Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib | Q40138493 | ||
| Insulin-like growth factor type 1 receptor expression correlates to good prognosis in highly malignant soft tissue sarcoma. | Q40465396 | ||
| Met receptor overexpression and oncogenic Ki-ras mutation cooperate to enhance tumorigenicity of colon cancer cells in vivo | Q40662025 | ||
| Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling | Q40758193 | ||
| Role of the IGF-I receptor in mutagenesis and tumor promotion | Q41386174 | ||
| Met and hepatocyte growth factor/scatter factor signal transduction in normal melanocytes and melanoma cells | Q41854163 | ||
| A novel recognition motif for phosphatidylinositol 3-kinase binding mediates its association with the hepatocyte growth factor/scatter factor receptor | Q41879451 | ||
| Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation | Q42798205 | ||
| Insulin-like growth factor-1 receptor in uveal melanoma: a predictor for metastatic disease and a potential therapeutic target | Q43843340 | ||
| Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study | Q46465639 | ||
| KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab | Q46903224 | ||
| The IGF-I receptor in cell growth, transformation and apoptosis | Q48684446 | ||
| Semi-parametric estimation of the binormal ROC curve for a continuous diagnostic test | Q51987020 | ||
| Mitogenic signaling of insulin-like growth factor I in MCF-7 human breast cancer cells requires phosphatidylinositol 3-kinase and is independent of mitogen-activated protein kinase | Q52191520 | ||
| EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients | Q62991747 | ||
| Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib | Q64135653 | ||
| Expression of insulin-like growth factor-1 receptor in human colorectal cancer | Q73114145 | ||
| Expression of the HGF/SF Receptor, c-met, and Its Ligand in Human Colorectal Cancers | Q73977662 | ||
| Expression of c-met Proto-oncogene in Primary Colorectal Cancer and Liver Metastases | Q74073409 | ||
| Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer | Q77555522 | ||
| Overexpression of the insulin-like growth factor I receptor in human colon carcinomas | Q78462813 | ||
| Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab | Q80704669 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | fish | Q152 |
| colorectal cancer | Q188874 | ||
| colorectal carcinoma | Q25493920 | ||
| cetuximab | Q420296 | ||
| P304 | page(s) | 83-89 | |
| P577 | publication date | 2008-06-24 | |
| P1433 | published in | British Journal of Cancer | Q326309 |
| P1476 | title | Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients | |
| P478 | volume | 99 |
| Q35584153 | A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy |
| Q24563539 | Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer |
| Q54611172 | Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer |
| Q38219290 | Anti-EGFR MoAb treatment in colorectal cancer: limitations, controversies, and contradictories |
| Q37636844 | Anti-epidermal growth factor receptor monoclonal antibody-based therapy for metastatic colorectal cancer: a meta-analysis of the effect of PIK3CA mutations in KRAS wild-type patients |
| Q39763068 | BEYOND KRAS: Other markers and potential treatment strategies for KRAS mutant and wild-type patients |
| Q37776505 | BRAF Mutation Testing in Colorectal Cancer |
| Q39213203 | BRAF V600E mutation and resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer: a meta-analysis |
| Q38238740 | Beyond KRAS: Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer. |
| Q37633765 | Biomarkers and anti-EGFR therapies for KRAS wild-type metastatic colorectal cancer |
| Q58698130 | Cell-Free DNA Profiling to Discover Mechanisms of Exceptional Response to Cabozantinib Plus Panitumumab in a Patient With Treatment Refractory Metastatic Colorectal Cancer |
| Q52599881 | Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability. |
| Q43723138 | Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer |
| Q34198721 | Chromogenic in situ hybridization to detect EGFR gene copy number in cell blocks from fine-needle aspirates of non small cell lung carcinomas and lung metastases from colo-rectal cancer |
| Q35051660 | Clinical impact of c-MET expression and genetic mutational status in colorectal cancer patients after liver resection. |
| Q37690299 | Clinical implications of MET gene copy number in lung cancer |
| Q35955198 | Combination Drug Delivery Approaches in Metastatic Breast Cancer |
| Q36257068 | Combination of cetuximab and PP242 synergistically suppress the progression of wild-type KRAS colorectal carcinoma |
| Q43805357 | Combined analysis of KRAS and PIK3CA mutations, MET and PTEN expression in primary tumors and corresponding metastases in colorectal cancer |
| Q37899687 | Concordance of predictive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: a review |
| Q38052918 | Concordant KRAS Mutations in Primary and Metastatic Colorectal Cancer Tissue Specimens: A Meta-Analysis and Systematic Review |
| Q53187961 | Copy number gain of PIK3CA and MET is associated with poor prognosis in head and neck squamous cell carcinoma. |
| Q51542320 | Correlation between Gene Expression of IGF-1R Pathway Markers and Cetuximab Benefit in Metastatic Colorectal Cancer |
| Q92816308 | Detection of the BRAF V600E Mutation in Colorectal Cancer by NIR Spectroscopy in Conjunction with Counter Propagation Artificial Neural Network |
| Q33927952 | Development of an integrated genomic classifier for a novel agent in colorectal cancer: approach to individualized therapy in early development. |
| Q37970537 | Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer |
| Q37790671 | EGFR and KRAS in colorectal cancer |
| Q27852970 | EGFR gene copy number as a predictive biomarker for resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer treatment: a meta-analysis |
| Q35067570 | Effectors of epidermal growth factor receptor pathway: the genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine |
| Q58849503 | Epidermal growth factor receptor gene copy number may predict lapatinib sensitivity in HER2-positive metastatic breast cancer |
| Q37294977 | High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue |
| Q27851892 | Impact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy: a pooled analysis of three trials. |
| Q43241630 | Implications of KRAS mutation status for the treatment of metastatic colorectal cancer |
| Q42545098 | Improving Response Rates to EGFR-Targeted Therapies for Head and Neck Squamous Cell Carcinoma: Candidate Predictive Biomarkers and Combination Treatment with Src Inhibitors |
| Q35926926 | Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients |
| Q38092886 | Individualized therapy for metastatic colorectal cancer. |
| Q38663388 | Insulin-like Growth Factor 1 Receptor Expression in Advanced Non-small-cell Lung Cancer and its Impact on Overall Survival |
| Q35994860 | Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients. |
| Q43040968 | Integrating molecular diagnostics into anticancer drug discovery. |
| Q35083740 | KRAS Mouse Models: Modeling Cancer Harboring KRAS Mutations |
| Q36039967 | KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Based and Economic Analysis |
| Q46012603 | KRAS mutation detection in colorectal cancer by a commercially available gene chip array compares well with Sanger sequencing |
| Q21128654 | KRAS mutational analysis for colorectal cancerApplication: Pharmacogenomic |
| Q35231369 | KRAS status and resistance to epidermal growth factor receptor tyrosine-kinase inhibitor treatment in patients with metastatic colorectal cancer: a meta-analysis |
| Q28076490 | Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer |
| Q33947318 | Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis |
| Q27027648 | Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer |
| Q38586367 | Minireview: Were the IGF Signaling Inhibitors All Bad? |
| Q54334205 | Molecular spectrum of KRAS, BRAF, and PIK3CA gene mutation: determination of frequency, distribution pattern in Indian colorectal carcinoma |
| Q36393095 | Molecular spectrum of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese colorectal cancer patients: analysis of 1,110 cases |
| Q37997543 | Molecular testing in melanoma |
| Q34621577 | New trends in epidermal growth factor receptor-directed monoclonal antibodies |
| Q37728856 | Oncogenic mutations as predictive factors in colorectal cancer |
| Q58614590 | Optimal use of EGFR inhibitors: challenges, new drugs and future directions |
| Q37349748 | Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models. |
| Q26992267 | PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis |
| Q34239801 | Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancer |
| Q36964450 | Personalized Medicine and Oncology Practice Guidelines: A Case Study of Contemporary Biomarkers in Colorectal Cancer |
| Q26822817 | Personalized treatment for advanced colorectal cancer: KRAS and beyond |
| Q37312970 | Pharmacogenetics of solid tumors: directed therapy in breast, lung, and colorectal cancer: a paper from the 2008 william beaumont hospital symposium on molecular pathology |
| Q38805790 | Potential biomarkers for anti-EGFR therapy in metastatic colorectal cancer |
| Q46125016 | Pre- and postassessment of nurse practitioners' knowledge of hereditary colorectal cancer |
| Q37421431 | Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models. |
| Q37697540 | Predictive and prognostic biomarkers with therapeutic targets in advanced colorectal cancer. |
| Q51044379 | Predictive and prognostic roles of BRAF mutation in patients with metastatic colorectal cancer treated with anti‐epidermal growth factor receptor monoclonal antibodies: A meta‐analysis |
| Q27015224 | Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies |
| Q34161089 | Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: Activation of MET as one mechanism for drug resistance |
| Q38014668 | Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: Beyond KRAS mutations |
| Q36115580 | Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy |
| Q39404068 | Relevance of MET activation and genetic alterations of KRAS and E-cadherin for cetuximab sensitivity of gastric cancer cell lines |
| Q38516244 | Role and mechanisms of resistance of epidermal growth factor receptor antagonists in the treatment of colorectal cancer. |
| Q38134309 | Role of cMET in the development and progression of colorectal cancer |
| Q37467394 | Should we be surprised at the paucity of response to EGFR inhibitors? |
| Q27027778 | Signaling cross-talk in the resistance to HER family receptor targeted therapy |
| Q44283525 | Study of MET protein levels and MET gene copy number in 72 sinonasal intestinal-type adenocarcinomas |
| Q37903703 | Systematic review of pharmacogenetic testing for predicting clinical benefit to anti-EGFR therapy in metastatic colorectal cancer |
| Q37177918 | TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy |
| Q34121895 | Targeted Therapies and Predictive Markers in Epithelial Malignancies of the Gastrointestinal Tract |
| Q34776118 | The Prognostic Role of BRAF Mutation in Metastatic Colorectal Cancer Receiving Anti-EGFR Monoclonal Antibodies: A Meta-Analysis |
| Q37496695 | The treatment of colorectal carcinoma with monoclonal antibodies: the importance of KRAS mutation analysis and EGFR status. |
| Q37640727 | Translating clinical research of Molecular Biology into a personalized, multidisciplinary approach of colorectal cancer patients |
| Q37225720 | Treatment in advanced colorectal cancer: what, when and how? |
| Q35713396 | Tumor budding in colorectal carcinoma assessed by cytokeratin immunostaining and budding areas: possible involvement of c-Met |
| Q51827376 | Unmasking the role of KRAS and BRAF pathways in MSI colorectal tumors |
| Q33965328 | Using genetics and genomics strategies to personalize therapy for cancer: focus on melanoma |
| Q36352462 | c-MET expression in colorectal adenomas and primary carcinomas with its corresponding metastases |
Search more.